These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 31902122)

  • 1. Vonicog alfa for the management of von Willebrand disease: a comprehensive review and single-center experience.
    Tran T; Arnall J; Moore DC; Ward L; Palkimas S; Man L
    J Thromb Thrombolysis; 2020 Apr; 49(3):431-440. PubMed ID: 31902122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Advances in the therapy for von Willebrand disease].
    Nakayama T
    Rinsho Ketsueki; 2023; 64(5):389-396. PubMed ID: 37271530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant von Willebrand factor: a first-of-its-kind product for von Willebrand disease.
    Singal M; Kouides PA
    Drugs Today (Barc); 2016 Dec; 52(12):653-664. PubMed ID: 28276537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Von Willebrand factor (Vonvendi®): the first recombinant product licensed for the treatment of von Willebrand disease.
    Franchini M; Mannucci PM
    Expert Rev Hematol; 2016 Sep; 9(9):825-30. PubMed ID: 27427955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An evaluation of von Willebrand factor (recombinant) therapy for adult patients living with severe type 3 von Willebrand disease.
    Hancock JM; Escobar MA
    Expert Rev Hematol; 2023 Mar; 16(3):157-161. PubMed ID: 36861346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of von Willebrand Disease.
    Curnow J; Pasalic L; Favaloro EJ
    Semin Thromb Hemost; 2016 Mar; 42(2):133-46. PubMed ID: 26838696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A personalized approach to the management of VWD.
    Phua CW; Berntorp E
    Transfus Apher Sci; 2019 Oct; 58(5):590-595. PubMed ID: 31466808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
    Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
    Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.
    Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; van de Velden A; Berneman Z
    Semin Thromb Hemost; 2006 Sep; 32(6):636-45. PubMed ID: 16977574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolution of replacement therapy for von Willebrand disease: From plasma fraction to recombinant von Willebrand factor.
    Peyvandi F; Kouides P; Turecek PL; Dow E; Berntorp E
    Blood Rev; 2019 Nov; 38():100572. PubMed ID: 31229334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of a high purity, double virus inactivated factor VIII/von Willebrand factor concentrate (Biostate) in patients with von Willebrand disorder requiring invasive or surgical procedures.
    Shortt J; Dunkley S; Rickard K; Baker R; Street A
    Haemophilia; 2007 Mar; 13(2):144-8. PubMed ID: 17286766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical efficacy of highly purified, doubly virus-inactivated factor VIII/von Willebrand factor concentrate (Fanhdi) in the treatment of von Willebrand disease: a retrospective clinical study.
    Federici AB; Baudo F; Caracciolo C; Mancuso G; Mazzucconi MG; Musso R; Schinco PC; Targhetta R; Mannuccio Mannucci P
    Haemophilia; 2002 Nov; 8(6):761-7. PubMed ID: 12410644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New treatment approaches to von Willebrand disease.
    Lavin M; O'Donnell JS
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):683-689. PubMed ID: 27913547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Highly purified VWF/FVIII concentrates in the treatment and prophylaxis of von Willebrand disease: the PRO. WILL Study.
    Federici AB
    Haemophilia; 2007 Dec; 13 Suppl 5():15-24. PubMed ID: 18078393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.
    Michiels JJ; van Vliet HH; Berneman Z; Schroyens W; Gadisseur A
    Acta Haematol; 2009; 121(2-3):167-76. PubMed ID: 19506363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of von Willebrand's disease.
    Aledort LM
    Mayo Clin Proc; 1991 Aug; 66(8):841-6. PubMed ID: 1907343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant von Willebrand factor prophylaxis in patients with severe von Willebrand disease: phase 3 study results.
    Leebeek FWG; Peyvandi F; Escobar M; Tiede A; Castaman G; Wang M; Wynn T; Baptista J; Wang Y; Zhang J; Mellgård B; Özen G
    Blood; 2022 Jul; 140(2):89-98. PubMed ID: 35439298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of von Willebrand disease with factor VIII/von Willebrand factor concentrates: results from current studies and surveys.
    Federici AB
    Blood Coagul Fibrinolysis; 2005 Apr; 16 Suppl 1():S17-21. PubMed ID: 15849522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of ristocetin cofactor activity in the management of von Willebrand disease.
    Ewenstein BM
    Haemophilia; 2001 Jan; 7 Suppl 1():10-5. PubMed ID: 11240613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.